News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2024
July 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
Paolo Cortesi discusses the value of axi-cel as a second-line treatment in patients with R/R LBCL – VJHemOnc
Photo of Paolo Cortesi from researchgate.net
May 28, 2024, 14:17

Paolo Cortesi discusses the value of axi-cel as a second-line treatment in patients with R/R LBCL – VJHemOnc

VJHemOnc shared on X:

“Paolo Cortesi (The University of Milano–Bicocca) discusses the value of axi-cel as a second-line treatment in patients with R/R LBCL in an insightful interview from EBMT2024.

Click here to check it out.” .

Link to video.
Source: VJHemOnc/X

Axi-cel cancer EBMT2024 OncoDaily Oncology Paolo Cortesi The University of Milano-Bicocca VJHemOnc
Blog
Jul 2, 2024, 17:41
Mukhtasar M. Alkali: Governments to prioritize Cervical Cancer Elimination affecting millions of women
Blog
Jul 2, 2024, 17:21
Amalya Sargsyan: One of Oncodaily’s top 10 promising drugs is showing great resuts at ESMOGI24
Blog
Jul 2, 2024, 17:11
Megan-Claire Chase: Serious challenges of 'surviving' breast cancer as a Black woman under 40
Blog
Jul 2, 2024, 16:22
Eric H Yang: Our talented housestaff research achievements
Blog
Jul 2, 2024, 16:08
Nelson Dusetti: Clinic and Digital Personalized Medicine seminar at the University of Corte
Blog
Jul 2, 2024, 16:00
Early registration for ASCOQLTY24 is open
Blog
Jul 2, 2024, 15:29
European Cancer Organisation - Join INTERACT EUROPE100!
Blog
Jul 2, 2024, 15:28
Sarah Louden: 2024 ASCO Direct Puerto Rico is an overwhelming success
Insight
Jul 2, 2024, 15:25
Gut microbiota associated with cancer immunotherapy outcomes
Insight
Jul 2, 2024, 15:20
Vincent Rajkumar’s 2024 update on diagnosis, risk stratification, and treatment of myeloma
Blog
Jul 2, 2024, 15:18
Rami Manochakian: 7 excellent peer-reviewed Lung Cancer articles from ASCO24 Educational Book
Insight
Jul 2, 2024, 15:14
Managing dose reduction without compromising outcomes of HR+ breast cancer